Skip to content
Screener

Opus Genetics IRD Q3 2025 earnings

Reported November 12, 2025 · Before market open

Revenue$3.1MBeat by $7.6K
EPS-$0.12Beat by $0.02
Revenue estimate$3.1M
EPS estimate-$0.14

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$1.5M
EPS estimate-$0.14

Financials

Q3 2025

Income statement

See full
Revenue$3.1M-20.4%
Operating income-$8.3M-3.8%
Net income-$17.5M-132%
EPS (diluted)-$0.25+13.8%

Balance sheet

See full
Cash & equivalents$30.8M-15.9%
Total debt$1.1M—
Total equity$6.0M-82.6%
Total assets$36.1M-10.6%

Cash flow

See full
Operating cash flow-$6.2M-20.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$98.85M—
Enterprise value$69.1M—
P/S6.8×—

Profitability

See full
Operating margin-445.4%+162pp
Net margin-466.1%+361pp

Returns & leverage

See full
Return on equity-338.8%-442pp
Debt / equity0.2×—
Current ratio1.2×-5.4×

FAQ

When did Opus Genetics report Q3 2025 earnings?
Opus Genetics (IRD) reported Q3 2025 earnings on November 12, 2025 before market open.
What were Opus Genetics's Q3 2025 revenue and EPS?
Opus Genetics reported revenue of $3.1M and eps of $-0.12 for Q3 2025.
Did Opus Genetics beat estimates in Q3 2025?
Revenue beat the consensus estimate of $3.1M by $7.6K. EPS beat the consensus estimate of $-0.14 by $0.02.
How did Opus Genetics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 20.4% from $3.9M a year earlier and eps grew 58.6% from $-0.29.
Where can I find Opus Genetics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001140361-25-041544) and the 10-Q periodic report (0001140361-25-041547) directly on SEC EDGAR. The filing index links above go to sec.gov.